MedicalResearch.com Interview with:
Patrizia Carrieri PhD
INSERM U912 – ORS PACA
IHU – Faculté de Médecine
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: This study is based on the longitudinal data of the French ANRS HEPAVIH cohort of patients with HIV and Hepatitis C co-infection. This cohort was set up thanks to a collaboration between INSERM (National Institute of health and medical research) UMR912 in Marseille, the ISPED (public health and epidemiology institute) in Bordeaux and several hospital/university sites. Our INSERM team in Marseille is specialized in the study of the impact of behaviors on HIV and HCV outcomes, including mortality.
We could think that HCV cure was enough to reduce mortality in HIV-HCV patients as the mortality risk was 80% lower in those who were cured of (i.e. who “cleared”) Hepatitis C thanks to treatment.
However, our study showed that, even after HCV cure, sociobehavioral factors still matter: drinking at least 3 cups of coffee a day was associated with a 50% reduction in mortality risk as well as not smoking which was also associated with a reduced mortality risk. This association between elevated coffee intake and reduced mortality risk is probably due to the properties of polyphenols contained in coffee which can protect the liver and also reduce inflammation.
MedicalResearch.com: What should clinicians and patients take away from your report?
Response: This research highlights the importance of behaviors – coffee drinking and not smoking in particular – to improve survival. This remains valid also in the era of HCV cure.
Physicians should monitor lifestyles in this population and promote interventions to change behaviors and maximize outcomes.
MedicalResearch.com: What recommendations do you have for future research as a result of this study?
Response: I think that major behavioral changes in HIV-HCV patients can result in improved survival. For this reason, it is important to design and conduct interventional research to change lifestyles and reduce the risk of comorbidities – metabolic disorders, cardiovascular disease and cancer in particular -which are still frequent in this population even after HCV cure.
MedicalResearch.com: Is there anything else you would like to add?
Response: I would like to thank the National Agency of AIDS and Hepatitis research (ANRS) which funded this research, all the patients who accepted to participate in this study and of course the HEPAVIH study group.
MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.
Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients
Carrieri, Maria Patrizia et al.
Journal of Hepatology , Volume 0 , Issue 0 ,
Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.